Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985062 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL30976497 | 1.00 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL3304900 | 0.85 | HTR2A (0.50) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL27351990 | 0.85 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL23592614 | 0.83 | SLC6A4 (0.41) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL3305211 | 0.82 | SMN1; SMN2 (0.58) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL8145700 | 0.82 | SMN1; SMN2 (0.58) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL10330624 | 0.81 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL3312647 | 0.81 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| SCHEMBL31381393 | 0.81 | TSHR (0.52) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273143-B1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO LTD (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | DALIAN WZ PROBIOTICS AD HEALTH CO., LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4273143-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Dalian WZ Probiotics AD Health Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-114685456-B | 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof | 大连万众益生大健康有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2022144002-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 大连万众益生大健康有限公司 | 2022-07-07 | — | — | WO | disclosed |
| CN-114685456-A | 2, 5-diketopiperazine compound derivative, preparation method thereof, pharmaceutical composition and application thereof | 大连万众益生大健康有限公司 | 2022-07-01 | — | — | CN | disclosed |
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9653754-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9620814-B2 | — | — | 2017-04-11 | — | — | US | disclosed |
| US-9515348-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20130280622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2535976-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120308881-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQEUOUS-ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120264010-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20100099031-A1 | NONAQUEOUS ELECTROLYTES AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERIES EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2166611-A1 | NONAQUEOUS ELECTROLYTE, AND RECHARGEABLE BATTERY WITH THE NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-5191079-A | Chemical intermediates for bactericides | KANEBO, LTD. (JP) | 1993-03-02 | — | — | US | disclosed |
| US-5166203-A | QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME | KANEBO, LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| CN-1059339-A | New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making | KANEBO LTD (JP) | 1992-03-11 | — | — | CN | disclosed |
| EP-0472826-A2 | Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound | KANEBO LTD. (JP) | 1992-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140941-A1 | DERIVATIVE OF 2,5-DIKETOPIPERAZINE COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | WEE1, WEE2, CYP51A1 | SLC6A4 2161/4885SLC6A2 1841/4885SLC6A3 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.